Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase…

By Vincent A. Miller, V. Hirsh, J. Cadranel, Yuh-Min Chen, Keunchil Park, Sang-We Kim, Caicun Zhou, W. Su, Mengzhao Wang, Yan Sun and 8 more. The Lancet Oncology, 2012

968 citations recorded by the source corpus.

Subfields: Molecular Biology, Oncology, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/4bc428124a8b94ab37f120b82f3748f359111cad

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Oncology

1. Jie Yang
2. S. Rosenberg

In Pulmonary and Respiratory Medicine

1. L. Sequist

Citations in the corpus

• AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. (2015, neutral): “Any grade 1 (5) 13 (22) 15 (17) 10 (16) 1 (5) 40 (16)”
• Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. (2013, methodology): “Afatinib had in vitro activity against the T790M variant(10) and improved PFS compared with placebo in a randomized phase III trial in an NSCLC population clinically enriched for the presence of such mutations.(30) Therefore, afatinib may inhibit the selective expansion of T790M clones and prolong P”
• Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. (2016, background): “Fifteen trials reported significant differences for PFS or TTP.(15,34-36,41,47,49,56,57,62-67) Additional data regarding key outcomes of interest are reported in Table 3(15,41,53,56,57) and in the Data Supplement.”
• Rociletinib in EGFR-mutated non-small-cell lung cancer. (2015, neutral): “Vomiting 18 (14) 5 (13) 2 (11) 2 (12) 4 (25) 5 (15) 0 13 (14)”